On the basis of the strong evidence of a causal link between hyperlipidemia and CHD (29) and the demonstration that ablating hepatic TRIB1 expression increased plasma levels of cholesterol, LDL-C, and triglyceride (15), the implication was, which seemed to be entirely consistent with results from genome-wide association studies (GWAS) (14), that increasing TRIB1 would be atheroprotective. The gene discussed is TRIB1; the disease is hyperlipidemia.